TNT achieved a 93.7% complete response rate and 87.5% organ preservation in stage I rectal cancer patients. TNT may offer an organ-preserving alternative to surgery, especially for low-lying tumors, ...

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer Total ...

Many patients with locally advanced rectal cancer treated with total neoadjuvant therapy in the OPRA trial achieved a complete or near-complete tumor response and were initially offered a ...

Patients with localized rectal cancer classified as low risk can skip neoadjuvant chemoradiotherapy (nCRT) with an acceptably low risk of local relapse, new research suggests. A prospective study of ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and T-cell engagers.

Neoadjuvant therapy with immunotherapy in pMMR/MSS rectal cancer shows high response rates and favorable surgical outcomes, with manageable safety profiles. Short-course chemoradiotherapy demonstrates ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A retrospective study of patients with distal rectal cancer at Memorial Sloan Kettering Cancer Center (MSK) has found a higher rate of local recurrence after intersphincteric resection with handsewn ...

Neoadjuvant capecitabine-oxaliplatin chemotherapy did not improve three-year disease-free survival compared to upfront ...

When someone is diagnosed with colorectal cancer—which includes both colon and rectal cancers—many people immediately think ...